Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.
Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, Colombo P, Bertuzzi M, Spina F, Amatu A, Lombardo R, Prata I, Scaglione F, Vighi GD, Severgnini B, Siena S, Giannattasio C, Boracchi P, Sartore-Bianchi A.
Vallerio P, et al. Among authors: vighi gd.
ESMO Open. 2022 Feb;7(1):100338. doi: 10.1016/j.esmoop.2021.100338. Epub 2021 Dec 15.
ESMO Open. 2022.
PMID: 34920290
Free PMC article.